Jackson Square Partners Amends PACB Stake as of Dec 31, 2023

TL;DR

**Jackson Square Partners still holds PACB, filed an amendment on their stake.**

AI Summary

Jackson Square Partners, LLC filed an amended SC 13G/A on February 9, 2024, indicating their ownership of Pacific Biosciences of California Inc. (PACB) common stock as of December 31, 2023. This filing is an amendment (Amendment No. 3), suggesting a change in their previously reported ownership stake. While the exact percentage isn't detailed in the provided text, the filing confirms their continued significant interest in PACB, which matters to investors as large institutional holdings can influence stock stability and market perception.

Why It Matters

This filing confirms Jackson Square Partners' ongoing institutional interest in Pacific Biosciences, which can signal confidence to other investors and potentially impact stock liquidity.

Risk Assessment

Risk Level: low — This is a routine amendment filing by an institutional investor, indicating no immediate significant risk or opportunity.

Analyst Insight

Investors should note that Jackson Square Partners, a significant institutional holder, continues to maintain a position in PACB, but the filing itself doesn't provide enough detail to infer a change in sentiment or a specific action. Further investigation into the percentage of ownership would be needed.

Key Players & Entities

• Jackson Square Partners, LLC (company) — the reporting person filing the SC 13G/A
• Pacific Biosciences of California, Inc. (company) — the subject company whose securities are being reported
• December 31, 2023 (date) — the date of the event which required the filing of the statement
• February 9, 2024 (date) — the filing date of the SC 13G/A

FAQ

From the Filing

0001104659-24-012568.txt : 20240209 0001104659-24-012568.hdr.sgml : 20240209 20240209064226 ACCESSION NUMBER: 0001104659-24-012568 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240209 DATE AS OF CHANGE: 20240209 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA, INC. CENTRAL INDEX KEY: 0001299130 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 161590339 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-85738 FILM NUMBER: 24611091 BUSINESS ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-521-8000 MAIL ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA INC DATE OF NAME CHANGE: 20050829 FORMER COMPANY: FORMER CONFORMED NAME: NANOFLUIDICS INC DATE OF NAME CHANGE: 20040729 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Jackson Square Partners, LLC CENTRAL INDEX KEY: 0001605911 ORGANIZATION NAME: IRS NUMBER: 800945254 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: ONE LETTERMAN DRIVE STREET 2: BUILDING A, SUITE A3-200 CITY: SAN FRANCISCO STATE: CA ZIP: 94129 BUSINESS PHONE: 4152164700 MAIL ADDRESS: STREET 1: ONE LETTERMAN DRIVE STREET 2: BUILDING A, SUITE A3-200 CITY: SAN FRANCISCO STATE: CA ZIP: 94129 SC 13G/A 1 tm245549d3_sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 3)* Pacific Biosciences of California Inc (Name of Issuer) Common (Title of Class of Securities) 69404D108 (CUSIP Number) 12/31/2023 (Date of Event Which Requires Filing of the Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: x Rule 13d-1(b) ¨ Rule 13d-1(c) ¨ Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 1. NAME OF REPORTING PERSONS Jackson Square Partners, LLC 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ¨ (b) ¨ 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 8,018,694 6. SHARED VOTING POWER 0 7. SOLE DISPOSITIVE POWER 9,704,766 8. SHARED DISPOSITIVE POWER None 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9,704,766 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨ 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.63% 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IA Item 1(a). Name of Issuer: Pacific Biosciences of California Inc Item 1(b). Address of Issuer’s Principal Executive Offices: 1305 O’Brien Drive Menlo Park, CA 94025 Item 2(a). Name of Person Filing: Jackson Square Partners, LLC Item 2(b). Address of Principal Business Office or, if none, Residence: One Letterman Drive Building A, Suite A3-200 San Francisco, CA 94129 Item 2(c). Citizenship: Delaware Item 2(d). Title of Class of Securities: Common Item 2(e). CUSIP Numbe